Showing results (21-30 of 47) with videos related to
Sort By:
Pageof 5
Medical Physics|March 25, 2017
Very high-energy electron (VHEE) beams in radiation therapy; Treatment plan comparison between VHEE, VMAT, and PPBSEmil Schüler, Kjell Eriksson, Elin Hynning, et al.World Neurosurgery|July 3, 2016
The Outcome of Hypofractionated Stereotactic Radiosurgery for Large Vestibular SchwannomasMario Teo, Michael Zhang, Amy Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2006
Screening for coronary artery disease after mediastinal irradiation for Hodgkin's diseasePaul A Heidenreich, Ingela Schnittger, H William Strauss, et al.Journal of Neurosurgery|January 23, 2026
Clinical and radiological outcomes of orbital metastases treated with stereotactic radiosurgery: a single-institution retrospective series and review of the literatureAroosa Zamarud, Yusuke S Hori, Ahed H Kattaa, et al.Journal of Neurosurgery|April 2, 2021
The Stanford stereotactic radiosurgery experience on 7000 patients over 2 decades (1999-2018): looking far beyond the scalpelNida Fatima, Antonio Meola, Victoria Y Ding, et al.International Journal of Radiation Oncology, Biology, Physics|July 22, 2015
Repeat Courses of Stereotactic Radiosurgery (SRS), Deferring Whole-Brain Irradiation, for New Brain Metastases After Initial SRSDavid B Shultz, Leslie A Modlin, Priya Jayachandran, et al.World Neurosurgery|August 28, 2020
Intracranial Tumor Control After Immune-Related Adverse Events and Discontinuation of Immunotherapy for MelanomaMichael Zhang, Adrian J Rodrigues, Hriday P Bhambhvani, et al.Journal of Neurosurgery. Spine|March 2, 2020
Local control and toxicity outcomes of stereotactic radiosurgery for spinal metastases of gastrointestinal originNavjot Sandhu, Kathryn R K Benson, Kiran A Kumar, et al.Practical Radiation Oncology|May 20, 2020
Stereotactic Radiosurgery for Resected Brain Metastases: Does the Surgical Corridor Need to be Targeted?Siyu Shi, Navjot Sandhu, Michael Jin, et al.Journal of Neuro-Oncology|January 8, 2021
Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastasesMichael Zhang, Adrian J Rodrigues, Erqi L Pollom, et al.Pageof 5